Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers

Open-label, crossover study recruiting 46 healthy male volunteers comparing the absorption of APO-dabigatran 150 mg per oral (PO) in the absence or presence of a proton pump inhibitor. Participants will serve as their own control when comparing dabigatran exposure in the absence or presence of the proton pump inhibitor, Rabeprazole 20 mg.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - RABEprazole 20 Mg Oral Delayed Release Tablet

Absorption of APO-Dabigatran measured with and without influence of rabeprazole

Drug - APO-Dabigatran 150mg

Absorption of APO-Dabigatran post single dose

Additional Information

Official Study Title

Impact of Rabeprazole-induced Elevated Gastric pH on APO-Dabigatran Exposure in Healthy Volunteers

Clinical Trial ID

NCT04157881

ParticipAid ID

aQW4Yd